Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mathijssen

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidaseRyan M Franke, Ashley M Kosloske, Cynthia S Lancaster, et al.
European Heart Journal. Cardiovascular Imaging|March 4, 2025
The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMRF Shuduyeva, A L M Bakker, F Akdim, et al.
Pharmacogenomics|July 30, 2016
Opioid treatment failure in cancer patients: the role of clinical and genetic factorsAstrid W Oosten, Maja Matic, Ron H van Schaik, et al.
Clinical Pharmacology and Therapeutics|July 19, 2013
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceJ A Sprowl, L van Doorn, S Hu, et al.
International Journal of Cardiology|February 14, 2021
Effectiveness and safety of infliximab in cardiac SarcoidosisA L M Bakker, H Mathijssen, J Azzahhafi, et al.
Clinical Pharmacology and Therapeutics|December 23, 2006
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter proteinF A de Jong, T J Scott-Horton, D L Kroetz, et al.
Psycho-Oncology|July 1, 2017
Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participationDiane A van der Biessen, Peer G van der Helm, Dennis Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Irinotecan (CPT-11) metabolism and disposition in cancer patientsA Sparreboom, M J de Jonge, P de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidaseRyan M Franke, Ashley M Kosloske, Cynthia S Lancaster, et al.
European Heart Journal. Cardiovascular Imaging|March 4, 2025
The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMRF Shuduyeva, A L M Bakker, F Akdim, et al.
Pharmacogenomics|July 30, 2016
Opioid treatment failure in cancer patients: the role of clinical and genetic factorsAstrid W Oosten, Maja Matic, Ron H van Schaik, et al.
Clinical Pharmacology and Therapeutics|July 19, 2013
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearanceJ A Sprowl, L van Doorn, S Hu, et al.
International Journal of Cardiology|February 14, 2021
Effectiveness and safety of infliximab in cardiac SarcoidosisA L M Bakker, H Mathijssen, J Azzahhafi, et al.
Clinical Pharmacology and Therapeutics|December 23, 2006
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter proteinF A de Jong, T J Scott-Horton, D L Kroetz, et al.
Psycho-Oncology|July 1, 2017
Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participationDiane A van der Biessen, Peer G van der Helm, Dennis Klein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Irinotecan (CPT-11) metabolism and disposition in cancer patientsA Sparreboom, M J de Jonge, P de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2024
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendationsDaniel L Hertz, Markus Joerger, Yung-Jue Bang, et al.
Anti-Cancer Drugs|April 9, 1999
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatinR H Mathijssen, R J van Alphen, M J de Jonge, et al.
Pageof 4